Compare First Trust Cloud Computing ETF (SKYY) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
First Trust Cloud Computing ETF vs Tango Therapeutics Inc. — how do they compare? First Trust Cloud Computing ETF trades at $164 (market cap $3.56B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.74B). The key difference: First Trust Cloud Computing ETF and Tango Therapeutics Inc. are close in size by market cap, and First Trust Cloud Computing ETF is trading nearer its 52-week high, Tango Therapeutics Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold First Trust Cloud Computing ETF for 84 Days and Tango Therapeutics Inc. for 0 Days on average.
| SKYY | TNGX | |
|---|---|---|
Market Cap | $3.56B | $3.74B |
Volume | 272,580 | 3,438,781 |
52-Week High | $174.89 | $32.90 |
52-Week Low | $104.16 | $7.50 |
Typical Hold Time | 84 Days | 0 Days |
Sector | — | Health |
Enterprise Value | — | $2.76B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
First Trust Cloud Computing ETF (SKYY) trades at $171.52, down 0.57% on the day but remains near its 52-week high of $169.41. Technical indicators show a bullish trend with strong moving average support, though RSI suggests mild overbought conditions. The ETF provides diversified exposure to cloud computing companies benefiting from AI adoption and digital transformation trends, with recent articles highlighting the sector's growth potential.
The cloud computing sector shows strong secular growth drivers including AI infrastructure spending and cloud migration. While technical momentum remains positive, investors should monitor valuation levels given the ETF's proximity to recent highs. Sector concentration and technology volatility present key risks, though institutional interest in cloud infrastructure remains robust.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About First Trust Cloud Computing ETF
The fund will normally invest at least 90% of its net assets (including investment borrowings) in the common stocks and depositary receipts that comprise the index. The index is designed to track the performance of companies involved in the cloud computing industry.
Read more on SKYY →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
